If considering systemic therapy, would you consider standard chemotherapy or use biomarker-directed therapy (e.g., imatinib if ckit+, larotrectinib/entrectinib if NTRK fusion identified, or immune checkpoint inhibitor if MSI, dMMR, TMB-H, or PD-L1+)?